| Issue Date |
Title |
Author(s) |
| 2016 |
Divergent lncRNAs Regulate Gene Expression and Lineage Differentiation in Pluripotent Cells |
Luo, Sai;Lu, Yuyang;Liu, Lichao;Yin, Yafei;Chen, Chunyan;Han, Xue;Wu, Bohou;Xu, Ronggang;Liu, Wei;Yan, Pixi;Shao, Wen;Lu, Zhi;Li, Haitao;Na, Jie;Tang, Fuchou;Wang, Jianlong;Zhang, Yong E.;Shen, Xiaohua |
| 2015 |
Emergence, Retention and Selection: A Trilogy of Origination for Functional De Novo Proteins from Ancestral LncRNAs in Primates |
Chen, Jia-Yu;Shen, Qing Sunny;Zhou, Wei-Zhen;Peng, Jiguang;He, Bin Z.;Li, Yumei;Liu, Chu-Jun;Luan, Xuke;Ding, Wanqiu;Li, Shuxian;Chen, Chunyan;Tan, Bertrand Chin-Ming;Zhang, Yong E.;He, Aibin;Li, Chuan-Yun |
| 2019 |
GenTree, an integrated resource for analyzing the evolution and function of primate-specific coding genes |
Shao, Yi;Chen, Chunyan;Shen, Hao;He, Bin Z.;Yu, Daqi;Jiang, Shuai;Zhao, Shilei;Gao, Zhiqiang;Zhu, Zhenglin;Chen, Xi;Fu, Yan;Chen, Hua;Gao, Ge;Long, Manyuan;Zhang, Yong E. |
| 15-Nov-2022 |
Is the 2nd Generation Tyrosine Kinase-Inhibitor a Better Initial Therapy Than Imatinib in Persons with Chronic Myeloid Leukemia Presenting in Accelerated Phase: A Multicenter Retrospective Study |
Yang, Sen;Zhang, Xiaoshuai;Zhang, Yanli;Du, Xin;Weng, Jianyu;Zhu, Huanling;Pan, Ling;Yang, Yun-fan;Meng, Li;Liu, Zhenfang;Liu, Xiaoli;Xu, Na;Chen, Chunyan;Wang, Xiaodong;Liang, Rong;Huang, Jian;Li, Guohui;Liu, Chunshui;Lin, Hai;Hu, Jianda;Fei, Li;Liu, Bingcheng;Li, Weiming;Liu, Zhuogang;Yang, Wei;Huang, Xiao Jun;Jiang, Qian |
| 15-Nov-2022 |
A Predictive Scoring System for Therapy Failure in Persons with Chronic Myeloid Leukemia Receiving Initial a Second-Generation Tyrosine Kinase Inhibitor Therapy |
Zhang, Xiaoshuai;Liu, Bingcheng;Huang, Jian;Zhang, Gongli;Liu, Xiaoli;Xu, Na;Li, Weiming;Du, Xin;Weng, Jianyu;Lin, Hai;Liang, Rong;Chen, Chunyan;Zhu, Huanling;Pan, Ling;Yang, Yun-fan;Wang, Xiaodong;Li, Guohui;Liu, Zhuogang;Liu, Zhenfang;Hu, Jianda;Liu, Chunshui;Fei, Li;Yang, Wei;Meng, Li;Gale, Robert Peter;Huang, Xiao Jun;Jiang, Qian |
| 15-Nov-2022 |
Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor |
Zhang, Xiaoshuai;Liu, Bingcheng;Huang, Jian;Zhang, Gongli;Liu, Xiaoli;Xu, Na;Li, Weiming;Du, Xin;Weng, Jianyu;Lin, Hai;Liang, Rong;Chen, Chunyan;Zhu, Huanling;Pan, Ling;Yang, Yun-fan;Wang, Xiaodong;Li, Guohui;Liu, Zhuogang;Liu, Zhenfang;Hu, Jianda;Liu, Chunshui;Fei, Li;Yang, Wei;Meng, Li;Gale, Robert Peter;Huang, Xiao Jun;Jiang, Qian |
| 15-Nov-2022 |
Validation and Use of Predictive Scoring Systems for Molecular Responses in 5,203 Persons with Chronic Myeloid Leukemia |
Zhang, Xiaoshuai;Liu, Bingcheng;Huang, Jian;Zhang, Gongli;Liu, Xiaoli;Xu, Na;Li, Weiming;Du, Xin;Weng, Jianyu;Lin, Hai;Liang, Rong;Chen, Chunyan;Zhu, Huanling;Pan, Ling;Yang, Yunfan;Wang, Xiaodong;Li, Guohui;Liu, Zhuogang;Liu, Zhenfang;Hu, Jianda;Liu, Chunshui;Fei, Li;Yang, Wei;Meng, Li;Gale, Robert Peter;Huang, Xiao Jun;Jiang, Qian |
